Pulmovant announces publication of PK, lung deposition data for mosliciguat

Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetics, PK, in healthy male volunteers following the administration of mosliciguat, a potential first-in-class, inhaled soluble Guanylate Cyclase activator with targeted delivery to the lungs and once-daily administration, designed to provide a treatment option for patients with pulmonary hypertension. The peer-reviewed manuscript titled, “Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat: Results from Randomized Phase I Studies in Healthy Men,” was published in the scientific journal Clinical Pharmacokinetics. These data suggest inhaled mosliciguat has a longer half-life compared to oral and IV administration, supporting further evaluation of once-daily dosing and the potential to have limited systemic side effects when administered to patients.